How sub can you sub­set? Eras­ca shores up case for test­ing its two lead can­di­dates in com­bo

It’s chal­leng­ing enough to get one can­cer drug ap­proved.

But it looks like Eras­ca is gun­ning for its two lead can­di­dates in com­bi­na­tion — though both are still in very ear­ly stages.

In its Q2 re­port, the San Diego-based biotech said it would read out ini­tial re­sults on its two lead can­di­dates lat­er in the year. And Eras­ca did just that Wednes­day, but rather than pre­sent­ing the re­sults of the two Phase I monother­a­py tri­als sep­a­rate­ly, Eras­ca tout­ed a pooled analy­sis of its two on­go­ing tri­als — one for ERAS-007, the ERK1/2 in­hibitor Eras­ca li­censed from Asana Bio­Sciences, and one for ERAS-601, an SHP2 in­hibitor — plus a past Asana tri­al of ERAS-007.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER